Cerebral amyloidoma
I. V. Grigoriev,
K. S. Esina,
O. O. Kordonskaya,
S. A. Mamykina,
O. I. Patsap,
S. A. Melchenko,
I. V. Senko,
M. B. Dolgushin https://doi.org/10.63769/1683-3295-2025-27-3-125-133
Abstract
Amyloidoma is a non-tumor lesion characterized by local deposits of insoluble protein aggregates of κ/λ immunoglobulin light chains in tissues. This condition is also known as AL-amyloidosis and it is not associated with systemic amyloidosis. The usage of term “amyloidoma” is due to the fact that this lesion acts like a tumor according to clinical and neurovisualization signs but it is not a tumor.
The correct diagnosis is difficult due to small number of described cases as well as absence of specific clinical symptoms and tumor-like natural history. The most reliable diagnostic method is histological examination. We present 2 clinical cases of cerebral amyloidoma, confirmed histologically.
About the Authors
I. V. Grigoriev
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Ilya V. Grigoriev.
Bld. 10, 1 Ostrovityanova St., Moscow 117513
K. S. Esina
Toksovskaya Clinical Interdistrict Hospital
Russian Federation
Russian Federation
18 Bulanova St., Toksovo Village, Leningrad Region 188664
O. O. Kordonskaya
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
S. A. Mamykina
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
O. I. Patsap
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
S. A. Melchenko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
I. V. Senko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
M. B. Dolgushin
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Bld. 10, 1 Ostrovityanova St., Moscow 117513
References
1. Pietruszewska W., Wągrowska-Danilewicz M., Klatka J. Amyloidosis of the head and neck: a clinicopathological study of cases with long-term follow-up. Arch Med Sci 2014;10(4):846–52. DOI: 10.5114/aoms.2013.39206
2. Löhr M., Kessler A.F., Monoranu C.M. et al. Primary brain amyloidoma, both a neoplastic and a neurodegenerative disease: a case report. BMC neurol 2019;19(1):59. DOI: 10.1186/s12883-019-1274-x
3. Safiullina E.I., Zinovyeva O.E., Rameev V.V., Kozlovskaya-Lysenko L.V. Peripheral nervous system involvement in systemic amyloidosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2018;10(3):12–8. (In Russ.). DOI: 10.14412/2074-2711-2018-3-12-18
4. Saltykow S. Zur frage des lokalen Amyloids der Hirngefaß̈e. Virchows Arch 1935;295:590. DOI: 10.1007/Bf01889298
5. Heß K., Purrucker J., Hegenbart U. et al. Cerebral amyloidoma is characterized by B-cell clonality and a stable clinical course. Brain Pathol 2018;28(2):234–9. DOI: 10.1111/bpa.12493
6. Bray D.P., Rich C.W., Ellis J.A. et al. Minimally invasive resection of intracerebral amyloidoma: case report and systematic review of the literature. World Neurosurg 2020;138:205–13. DOI: 10.1016/j.wneu.2020.02.072
7. Shiao J.C., Wolf A.B., Rabinovitch R.A. et al. Long-term control of primary cerebral ALH amyloidoma with focal radiation therapy. Adv Radiat Oncol 2021;7(2):100831. DOI: 10.1016/j.adro.2021.100831
8. Rostagno A., Holton J.L., Lashley T. et al. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci 2010;67(4):581–600. DOI: 10.1007/s00018-009-0182-4
9. Swanson A., Giannini C., Link M. et al. Trigeminal amyloidoma: a report of two cases and review of the literature. J Neurol Surg B Skull Base 2020;81(6):620–6. DOI: 10.1055/s-0039-1693111
10. Landau D., Avgeropoulos N., Ma J. Cerebral amyloidoma mimicking intracranial tumor: a case report. J Med Case Rep 2010;4:308. DOI: 10.1186/1752-1947-4-308
11. Pace A.A., Lownes S.E., Shivane A. et al. A tale of the unexpected: amyloidoma associated with intracerebral lymphoplasmacytic lymphoma. J Neurol Sci 2015;359(1–2):404–8. DOI: 10.1016/j.jns.2015.09.372
12. Fischer B., Palkovic S., Rickert C. et al. Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient. Amyloid 2007;14(1):11–9. DOI: 10.1080/13506120600960585
13. Radmanesh A., Wood M.D., Bollen A.W. Cerebral amyloidoma: a mimicker of granulomatous disease on brain MRI. J Neuroradiol 2019;46(5):336–9. DOI: 10.1016/j.neurad.2019.02.009
14. Rozenblum L., Bertaux M., Bielle F. et al. 18F-FDOPA PET/CT findings in a patient with primary cerebral amyloidoma. Clin Nucl Med 2020;45(4):e206–e7. DOI: 10.1097/RLU.0000000000002959
15. Karbowniczek A., Wierzba-Bobrowicz T., Mendel T., Nauman P. Cerebral amyloid angiopathy manifested as a brain tumour. clinical and neuropathological characteristics of two cases. Folia Neuropathol 2012;50(2):194–200.
16. Meier T., Hazenfield J.M., Girnius S. A rare case of central nervous system amyloidoma treated with fractionated radiotherapy. J Neurosurg 2017;127(2):338–41. DOI: 10.3171/2016.7.Jns1690
17. Smirnova A.G., Bondarenko S.N., Kisina A.A. et al. Current therapies for AL amyloidosis: literature review and our data. Klinicheskaya onkogematologiya = Clinical Oncohematology 2013;6(3):303–11. Available at: https://bloodjournal.ru/index.php/coh/article/view/673/627
Review
For citations:
Grigoriev I.V., Esina K.S., Kordonskaya O.O., Mamykina S.A., Patsap O.I., Melchenko S.A., Senko I.V., Dolgushin M.B. Cerebral amyloidoma. Russian journal of neurosurgery. 2025;27(3):125-133. https://doi.org/10.63769/1683-3295-2025-27-3-125-133
Views:
111
Email this article 